Business Context and Reporting Period
Company: Editas Medicine, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 16, 2016
Event: Entry into Material Definitive Agreements regarding gene editing intellectual property.
Key Financial Metrics and Obligations
This filing details new financial obligations arising from three agreements with the Broad Institute, Harvard, MIT, and other academic institutions. No revenue, profit, or cash flow data is provided in this specific filing.
- Upfront Payments (Cpf1 License): Mid-seven-digit aggregate cash fee plus $10.0 million in Initial Promissory Notes (4.8% interest, convertible to common stock).
- Upfront Payments (Cas9-II License): Low-seven-digit cash fee plus mid-five-figure annual maintenance fee.
- Maximum Potential Milestone Payments (Cpf1):
- Clinical/Regulatory: Up to $20.0 million per product (standard) or $6.0 million (Ultra-Orphan).
- Sales Milestones: Up to $54.0 million per product (standard) or $36.0 million (Ultra-Orphan).
- Success Payments (Market Cap/Sale): Up to $125.0 million aggregate cap.
- Maximum Potential Milestone Payments (Cas9-II):
- Clinical/Regulatory: Up to $3.7 million per product (standard) or $1.1 million (Ultra-Orphan).
- Sales Milestones: Up to $13.5 million per product (standard) or $9.0 million (Ultra-Orphan).
- Success Payments (Market Cap/Sale): Up to $30.0 million aggregate cap.
- Royalties: Mid-single-digit percentages on human disease products; sub-single-digit to high-single-digit on other products.
Material Changes and Agreements
On December 16, 2016, Editas entered into the following agreements:
- Cpf1 License Agreement: Exclusive, worldwide license for Cpf1 patent rights (gene editing) from Broad, Harvard, MIT, Wageningen University, and University of Tokyo. Includes obligations to achieve development milestones or face termination.
- Amendment to Existing License Agreement: Amended the 2014 CRISPR/Cas9 and TALE license. Excluded fields such as human germline modification, plant agriculture, and sterile seeds. Converted three specific targets to non-exclusive licenses.
- Cas9-II License Agreement: Exclusive license for specific Cas9 compositions of matter from Broad, MIT, Harvard, and University of Iowa Research Foundation.
Outlook, Risks, and Contingencies
- Termination Risks: Broad may terminate the Cpf1 agreement if Editas fails to meet development milestones, challenges patent validity, or enters bankruptcy. Editas may terminate at will with four months' notice.
- Third-Party Licensing: Broad retains the right to grant licenses to third parties for specific gene targets if Editas is not actively developing a product for that target or cannot demonstrate a commercially reasonable plan.
- Change of Control: In the event of a sale or change of control, promissory notes become immediately due in cash, and certain milestone payments increase by mid-double-digit percentages.
- Intellectual Property Control: Broad retains control of patent prosecution; Editas must reimburse expenses and share litigation recoveries.
Investor Verification Checklist
- Verify the exact amount of the "mid-seven-digit" and "low-seven-digit" upfront cash fees paid.
- Confirm the terms and conversion price of the $10.0 million Initial Promissory Notes.
- Assess the impact of the "milestone failure" clauses on the company's ability to retain exclusive rights to key gene targets.
- Review the specific definition of "Ultra-Orphan Disease" to understand the lower tier of milestone payments.
- Monitor the company's progress on development milestones to avoid potential termination of the Cpf1 license.